Navigation Links
Chimerix Announces Late-Breaker Presentation at 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting
Date:9/16/2011

irus (HSV), and JC virus (JCV), for which there are no FDA-approved treatments or where patients have failed available treatments. There is no evidence of otherwise unexplained nephrotoxicity or myelosuppression in these immunocompromised patients. These data support positive interim results seen in CMX001's ongoing Phase 2 placebo-controlled clinical trial evaluating the safety, tolerability and ability of CMX001 to prevent or control CMV infection in R+ hematopoietic cell transplant (HCT) recipients.  

About CMX001

CMX001 is an oral Lipid-Antiviral-Conjugate (LAC) that delivers high intracellular levels of the active antiviral agent cidofovir-diphosphate.  Its broad spectrum activity against double-stranded DNA (dsDNA) viruses without the myelotoxicity and nephrotoxicity of current agents has the potential to improve outcomes for immunosuppressed patients.  In development for the treatment or prevention of life-threatening dsDNA viral diseases, more than 600 patients have been dosed with CMX001 in placebo-controlled clinical trials and open-label treatment protocols.  More than 300 of these individuals have received CMX001 under Emergency Investigational New Drug Applications (EINDs) or as part of the CMX001-350 Open-Label Study to help treat life-threatening dsDNA viral diseases for which there were no other therapeutic options.  CMX001 is also being developed as a biodefense countermeasure in the event of a smallpox release.  The growing body of evidence of CMX001's antiviral activity against all five families of dsDNA viruses that cause disease in humans, including smallpox, has strengthened the compound's potential as a dual-use product prescribed as a traditional pharmaceutical and stockpiled as a biodefense countermeasure.  

Clinical studies of CMX001 include an ongoing Phase 2 study for the prevention cytomegalovirus (CMV) in adult hematopoietic cell transplant patients (CMX001-201); a Phase 2 s
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
2. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
3. Chimerix to Present at Two Upcoming Investor Conferences
4. Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
5. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
6. Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development
7. Chimerix to Present at 9th Annual BIO Investor Forum
8. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
9. Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
10. Chimerixs Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
11. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... July 23, 2014 PositiveID Corp. (OTCQB: PSID), ... , is an emerging player in the bio-threat ... bio-threat detection and rapid medical testing. The Company,s ... Bio-agent Autonomous Networked Detector), was developed under contract ... Science & Technology directorate, and $30 million of ...
(Date:7/23/2014)... Research and Markets has announced the addition ... Markets Worldwide 2014" report to their offering. ... purpose of this report is to analyze and size ... Gloves. The report discusses key players and identifies trends ... covered include product definitions, strategies, competitive analysis, market shares, ...
(Date:7/23/2014)... , July 23, 2014  The management team ... ) will hold a conference call on July ... second quarter ended June 30, 2014.  The call ... 2014Time: , 8:30 am EDTDial-in numbers: , Toll ... (412) 317-0790Webcast (live & archive): , www.columbialabs.com ...
Breaking Medicine Technology:PositiveID Analyst Inspection: Emerging Contender in BioThreat Detection - First Ever Revenue Guidance and Backlog Position Company for Increased Visibility and Traction - by SmallCapTraders.com 2Disposable Medical Gloves (Exam and Surgical) Markets Worldwide 2014 2Disposable Medical Gloves (Exam and Surgical) Markets Worldwide 2014 3Disposable Medical Gloves (Exam and Surgical) Markets Worldwide 2014 4Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 2
... MAQUET Cardiovascular LLC today announced the launch ... VASOSHIELD Pressure Controlling Syringe for use during Coronary Artery ... "flushing" pressure and controls vessel distension when harvested grafts ... Avoiding excessive pressure and limiting distension help maintain internal ...
... N.J. , May 3 Covance Inc. (NYSE: CVD ... Health Care Conference on Tuesday, May 4, 2010 at 1:30 ... www.covance.com .  In order to register and download any necessary software, please ... , Covance, ...
Cached Medicine Technology:MAQUET Cardiovascular Introduces New VASOSHIELD Pressure Controlling Syringe to Help Preserve Graft Integrity for Coronary Artery Bypass Surgery Patients 2MAQUET Cardiovascular Introduces New VASOSHIELD Pressure Controlling Syringe to Help Preserve Graft Integrity for Coronary Artery Bypass Surgery Patients 3MAQUET Cardiovascular Introduces New VASOSHIELD Pressure Controlling Syringe to Help Preserve Graft Integrity for Coronary Artery Bypass Surgery Patients 4
(Date:7/23/2014)... of research suggesting a safe and effective role ... cancer, with fewer detrimental side effects and improved ... study will be published in final format today ... Endocrinology . , Breast cancer is the most ... States. Approximately 70% of breast cancers are diagnosed ...
(Date:7/23/2014)... July 23, 2014 Rich Dad® Education, a ... of their charity yard sale to support Habit for Humanity ... 100% of the proceeds will be donated to Habitat for ... are being donated to the Habitat for Humanity ReStore thrift ... 33903. , One of the highlights of the yard ...
(Date:7/23/2014)... York (PRWEB) July 23, 2014 Thousands ... to move forward in a federal multidistrict litigation underway ... Liebhard LLP reports. According to an Order dated July ... hospital’s bid for payment of a $1,000 fee for ... implant. , Among other things, the Order noted ...
(Date:7/23/2014)... better treating the pernicious disorders of obesity and dementia ... American University,s Center for Behavioral Neuroscience. In the paper, ... aimed at areas of the brain responsible for memory ... could play a role in reducing certain dementias., "In ... measures often fall short. This is a new way ...
(Date:7/23/2014)... Olympic gold medal-winning speed skater Chad ... Friday, July 18. Hedrick visited Roanoke as the special ... an Olympic-style event celebrating its 25th Anniversary in 2014. ... premier sponsor of the Commonwealth Games, which like Foot ... and all activity levels. , Hedrick, a native of ...
Breaking Medicine News(10 mins):Health News:Hormones after breast cancer: Not fuel for the fire after all? 2Health News:Hormones after breast cancer: Not fuel for the fire after all? 3Health News:Hormones after breast cancer: Not fuel for the fire after all? 4Health News:Hormones after breast cancer: Not fuel for the fire after all? 5Health News:Rich Dad Education Charity Yard Sale Raises Over $650 for Habitat for Humanity of Lee and Hendry Counties 2Health News:DePuy Pinnacle Hip Lawsuits Move Forward, as Federal Judge Denies Hospital Bid for $1000 Explant Fee, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Hip Lawsuits Move Forward, as Federal Judge Denies Hospital Bid for $1000 Explant Fee, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Hip Lawsuits Move Forward, as Federal Judge Denies Hospital Bid for $1000 Explant Fee, Bernstein Liebhard LLP Reports 4Health News:Targeting the brain to treat obesity 2Health News:Targeting the brain to treat obesity 3Health News:US Olympian Chad Hedrick Visits Foot Levelers 2
... , ... Care of Serious Illness is the first book to provide a comprehensive look at the ... E. Meier, Stephen L. Isaacs, Robert Hughes (Editors) , ... New York, NY (Vocus) April 1, 2010 -- Palliative Care: Transforming ...
... they know how cytomegalovirus continues to re-infect people , THURSDAY, ... how a virus known as cytomegalovirus (CMV), which infects up ... re-infects people again and again even though their immune systems ... always make people ill, but certain people, such as newborns ...
... SNM and the Radiological Society of North America (RSNA) ... at the Natcher Conference Center of the National Institutes ... workshop will focus on general issues of standardization to ... and analysis of images in clinical trials. The second ...
... beat vitamin B for those with scent-robbing viral infection, ... Acupuncture may help people who lose their sense of ... a new study, 15 patients with post-viral olfactory dysfunction ... acupuncture. These patients were compared with PVOD patients treated ...
... new study of brain activity in depressed and anxious people ... modified for better or for worse by anxiety. ... Behavioral Neuroscience , looked at depression and two types of ... panic; and anxious apprehension, better known as worry. The ...
... ... Mac platforms , ... Richardson, TX (PRWEB) April 1, 2010 -- Damaka, a technology pioneer in Mobile ... Real-time 2-way Video, Application Sharing) Sweeping™ between laptops and mobile devices earlier in May ...
Cached Medicine News:Health News:Palliative Care: Transforming the Care of Serious Illness 2Health News:Palliative Care: Transforming the Care of Serious Illness 3Health News:Demystifying a Common, Persistent Virus 2Health News:FDA, SNM and RSNA host April 13-14 two-topic imaging workshop 2Health News:Depressed? Fearful? It might help to worry, too 2Health News:Damaka Delivers Advanced Sweeping™ Capability of Live Sessions Across Multiple Devices Over WiFi, 3G and 4G Networks 2
Full plate covers seal all 24 MicroAmp tubes...
96-Well PCR Plate Sealing Mat...
Easy to pierce, remove using foil stripper...
Inquire...
Medicine Products: